ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis

Company Overview

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Key Stats

• Today's Range: $8.64 to $9.08
• 50-Day Range: $8.65 to $11.60
• 52-Week Range: $8.51 to $17.02
• Volume: 259,559 shs
• Average Volume: 93,310 shs
• Market Capitalization: $555.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.80
• Consensus Rating: Moderate Buy

ABIVAX Société Anonyme Stock Analysis - MarketRank™

ABIVAX Société Anonyme scored higher than 54% of companies evaluated by MarketBeat, and ranked 435th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

ABIVAX Société Anonyme has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.86) per share.

Price to Book Value per Share Ratio

ABIVAX Société Anonyme has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.35% of the float of ABIVAX Société Anonyme has been sold short.

Short Interest Ratio / Days to Cover

ABIVAX Société Anonyme has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ABIVAX Société Anonyme has recently decreased by 15.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ABIVAX Société Anonyme does not currently pay a dividend.

Dividend Growth

ABIVAX Société Anonyme does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.35% of the float of ABIVAX Société Anonyme has been sold short.

Short Interest Ratio / Days to Cover

ABIVAX Société Anonyme has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ABIVAX Société Anonyme has recently decreased by 15.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.46

News Sentiment

ABIVAX Société Anonyme has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.

Percentage Held by Institutions

47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABVX Stock Analysis - Frequently Asked Questions

How have ABVX shares performed this year?

ABIVAX Société Anonyme's stock was trading at $10.70 at the beginning of the year. Since then, ABVX shares have decreased by 17.9% and is now trading at $8.78.
View the best growth stocks for 2024 here.

When did ABIVAX Société Anonyme IPO?

ABIVAX Société Anonyme (ABVX) raised $217 million in an IPO on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share.

Who are ABIVAX Société Anonyme's major shareholders?

ABIVAX Société Anonyme's top institutional investors include Great Point Partners LLC (3.36%), Point72 Asset Management L.P. (0.86%), Janus Henderson Group PLC (0.65%) and abrdn plc (0.50%).

How do I buy shares of ABIVAX Société Anonyme?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ABIVAX Société Anonyme own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ABIVAX Société Anonyme investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX) and Howard Hughes (HHH).

Company Calendar

• Today: 11/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABVX
• Previous Symbol: NASDAQ:ABVX
• CUSIP: N/A
• CIK: 1956827
• Web: www.abivax.com
• Phone: 33-1-53-83-09-63
• Fax: N/A
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $39.80
• High Stock Price Target: $50.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +353.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 3.04
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.37 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 63,290,000
• Free Float: N/A
• Market Cap: $555.69 million
• Optionable: Not Optionable
• Beta: N/A